AU780634C - Gene Therapy for treating ocular-related disorders - Google Patents
Gene Therapy for treating ocular-related disordersInfo
- Publication number
- AU780634C AU780634C AU36818/01A AU3681801A AU780634C AU 780634 C AU780634 C AU 780634C AU 36818/01 A AU36818/01 A AU 36818/01A AU 3681801 A AU3681801 A AU 3681801A AU 780634 C AU780634 C AU 780634C
- Authority
- AU
- Australia
- Prior art keywords
- nucleic acid
- vector
- acid sequence
- expression vector
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000001415 gene therapy Methods 0.000 title description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 142
- 239000013604 expression vector Substances 0.000 claims description 141
- 238000000034 method Methods 0.000 claims description 118
- 239000013598 vector Substances 0.000 claims description 117
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 106
- 210000004027 cell Anatomy 0.000 claims description 92
- 230000033115 angiogenesis Effects 0.000 claims description 79
- 239000003112 inhibitor Substances 0.000 claims description 73
- 206010029113 Neovascularisation Diseases 0.000 claims description 66
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 60
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 55
- 230000014509 gene expression Effects 0.000 claims description 52
- 239000003900 neurotrophic factor Substances 0.000 claims description 52
- 108090000102 pigment epithelium-derived factor Proteins 0.000 claims description 51
- 230000001225 therapeutic effect Effects 0.000 claims description 49
- 239000013603 viral vector Substances 0.000 claims description 46
- 230000000508 neurotrophic effect Effects 0.000 claims description 43
- 208000002780 macular degeneration Diseases 0.000 claims description 38
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 37
- 239000003795 chemical substances by application Substances 0.000 claims description 34
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 32
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 29
- 230000002950 deficient Effects 0.000 claims description 29
- 210000001525 retina Anatomy 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 22
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 12
- 108090000994 Catalytic RNA Proteins 0.000 claims description 10
- 102000053642 Catalytic RNA Human genes 0.000 claims description 10
- 230000000692 anti-sense effect Effects 0.000 claims description 10
- 108091092562 ribozyme Proteins 0.000 claims description 10
- 230000002792 vascular Effects 0.000 claims description 10
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 9
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000003161 choroid Anatomy 0.000 claims description 6
- 230000001886 ciliary effect Effects 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 210000004498 neuroglial cell Anatomy 0.000 claims description 4
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 claims description 4
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 230000001537 neural effect Effects 0.000 claims description 3
- 210000001585 trabecular meshwork Anatomy 0.000 claims description 3
- 210000001130 astrocyte Anatomy 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 210000002950 fibroblast Anatomy 0.000 claims description 2
- 210000000327 mueller cell Anatomy 0.000 claims description 2
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 claims 3
- 239000000049 pigment Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 48
- 102100035846 Pigment epithelium-derived factor Human genes 0.000 description 45
- 208000035475 disorder Diseases 0.000 description 43
- 230000000694 effects Effects 0.000 description 28
- 238000013518 transcription Methods 0.000 description 26
- 230000035897 transcription Effects 0.000 description 26
- 238000011282 treatment Methods 0.000 description 23
- 102000039446 nucleic acids Human genes 0.000 description 22
- 108020004707 nucleic acids Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 241000701161 unidentified adenovirus Species 0.000 description 22
- 101710132601 Capsid protein Proteins 0.000 description 21
- 101710094648 Coat protein Proteins 0.000 description 21
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 21
- 101710125418 Major capsid protein Proteins 0.000 description 21
- 101710141454 Nucleoprotein Proteins 0.000 description 21
- 101710083689 Probable capsid protein Proteins 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 108700019146 Transgenes Proteins 0.000 description 18
- 241000700605 Viruses Species 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- 238000012217 deletion Methods 0.000 description 14
- 230000037430 deletion Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 14
- 201000004569 Blindness Diseases 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 238000001727 in vivo Methods 0.000 description 13
- 208000022873 Ocular disease Diseases 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 108020003175 receptors Proteins 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 230000036961 partial effect Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 230000004393 visual impairment Effects 0.000 description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 9
- 241000725303 Human immunodeficiency virus Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 206010038848 Retinal detachment Diseases 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 208000028867 ischemia Diseases 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000000649 photocoagulation Effects 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 108700039887 Essential Genes Proteins 0.000 description 6
- 208000007135 Retinal Neovascularization Diseases 0.000 description 6
- 108700026226 TATA Box Proteins 0.000 description 6
- 108091023040 Transcription factor Proteins 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000002085 persistent effect Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- 230000004264 retinal detachment Effects 0.000 description 6
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 6
- 230000001177 retroviral effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000011144 upstream manufacturing Methods 0.000 description 6
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 201000007737 Retinal degeneration Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- -1 but not limited to Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229940053128 nerve growth factor Drugs 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 101001015103 Catostomus commersonii Isotocin receptor Proteins 0.000 description 4
- 208000035473 Communicable disease Diseases 0.000 description 4
- 101001040800 Homo sapiens Integral membrane protein GPR180 Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- 206010038934 Retinopathy proliferative Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 108091006116 chimeric peptides Proteins 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000035800 maturation Effects 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000004258 retinal degeneration Effects 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- 230000029812 viral genome replication Effects 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 108090000565 Capsid Proteins Proteins 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 208000001344 Macular Edema Diseases 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
- 208000002367 Retinal Perforations Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 201000007917 background diabetic retinopathy Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001775 bruch membrane Anatomy 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 3
- 230000001414 neuropoietic effect Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000008488 polyadenylation Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000016623 Choroid neoplasm Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 206010011715 Cyclitis Diseases 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010065630 Iris neovascularisation Diseases 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 102100030335 Midkine Human genes 0.000 description 2
- 108010092801 Midkine Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000099 Neurotrophin-4 Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 201000002154 Pterygium Diseases 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 108020005067 RNA Splice Sites Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 208000016624 Retinal neoplasm Diseases 0.000 description 2
- 208000014139 Retinal vascular disease Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 102000004330 Rhodopsin Human genes 0.000 description 2
- 108090000820 Rhodopsin Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010047050 Vascular anomaly Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000037919 acquired disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000002159 anterior chamber Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000002588 choroid cancer Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000000695 crystalline len Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011496 digital image analysis Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000000574 ganglionic effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108060003196 globin Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000003641 microbiacidal effect Effects 0.000 description 2
- 229940124561 microbicide Drugs 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 201000003142 neovascular glaucoma Diseases 0.000 description 2
- 230000006576 neuronal survival Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 208000020911 optic nerve disease Diseases 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000003094 perturbing effect Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 108010072683 pigment epithelium-derived factor receptor Proteins 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001124 posttranscriptional effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 102000023888 sequence-specific DNA binding proteins Human genes 0.000 description 2
- 108091008420 sequence-specific DNA binding proteins Proteins 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000003584 silencer Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000000015 thermotherapy Methods 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 208000026726 vitreous disease Diseases 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000037859 AIDS-related disorder Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 244000036975 Ambrosia artemisiifolia Species 0.000 description 1
- 235000003129 Ambrosia artemisiifolia var elatior Nutrition 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 102000009840 Angiopoietins Human genes 0.000 description 1
- 108010009906 Angiopoietins Proteins 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 108010020650 COUP Transcription Factor II Proteins 0.000 description 1
- 102100028226 COUP transcription factor 2 Human genes 0.000 description 1
- 206010059449 Candida endophthalmitis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000004652 Cardiovascular Abnormalities Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000033810 Choroidal dystrophy Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- 206010008790 Choroidal rupture Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 201000003101 Coloboma Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 206010014666 Endocarditis bacterial Diseases 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 1
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000219726 Griffonia simplicifolia Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 102100031000 Hepatoma-derived growth factor Human genes 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 101001083798 Homo sapiens Hepatoma-derived growth factor Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 101710086709 Lectin B4 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025412 Macular dystrophy congenital Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101710193418 Myosin light chain 1 Proteins 0.000 description 1
- 102100030740 Myosin light chain 1/3, skeletal muscle isoform Human genes 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- 102100035384 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Human genes 0.000 description 1
- 101710098657 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 2 Proteins 0.000 description 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 1
- 206010029279 Neurogenic bladder Diseases 0.000 description 1
- 102000004230 Neurotrophin 3 Human genes 0.000 description 1
- 108090000742 Neurotrophin 3 Proteins 0.000 description 1
- 102000003683 Neurotrophin-4 Human genes 0.000 description 1
- 102100033857 Neurotrophin-4 Human genes 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000021957 Ocular injury Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 101710173835 Penton protein Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 206010064714 Radiation retinopathy Diseases 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 208000032400 Retinal pigmentation Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 102100038247 Retinol-binding protein 3 Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 208000020764 Sensation disease Diseases 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150081494 TMPO gene Proteins 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 235000003484 annual ragweed Nutrition 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000009361 bacterial endocarditis Diseases 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000006263 bur ragweed Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000015861 cell surface binding Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 208000003571 choroideremia Diseases 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 235000003488 common ragweed Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 210000000188 diaphragm Anatomy 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000013534 fluorescein angiography Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 210000000873 fovea centralis Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000009540 indirect ophthalmoscopy Methods 0.000 description 1
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 description 1
- 229960004657 indocyanine green Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010048996 interstitial retinol-binding protein Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000281 neuronotrophic effect Effects 0.000 description 1
- 229940032018 neurotrophin 3 Drugs 0.000 description 1
- 229940097998 neurotrophin 4 Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000000299 nuclear matrix Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000034503 punctate inner choroidopathy Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 235000009736 ragweed Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 210000002301 subretinal fluid Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18174300P | 2000-02-11 | 2000-02-11 | |
| US60/181743 | 2000-02-11 | ||
| US09/599997 | 2000-06-23 | ||
| US09/599,997 US6821775B1 (en) | 2000-02-11 | 2000-06-23 | Viral vector encoding pigment epithelium-derived factor |
| US22833700P | 2000-08-28 | 2000-08-28 | |
| US60/228337 | 2000-08-28 | ||
| PCT/US2001/004203 WO2001058494A2 (en) | 2000-02-11 | 2001-02-09 | Gene therapy for treating ocular-related disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005202935A Division AU2005202935A1 (en) | 2000-02-11 | 2005-07-06 | Gene therapy for treating ocular-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU3681801A AU3681801A (en) | 2001-08-20 |
| AU780634B2 AU780634B2 (en) | 2005-04-07 |
| AU780634C true AU780634C (en) | 2006-02-23 |
Family
ID=27391455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU36818/01A Ceased AU780634C (en) | 2000-02-11 | 2001-02-09 | Gene Therapy for treating ocular-related disorders |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1253948A2 (https=) |
| JP (1) | JP2003522160A (https=) |
| AU (1) | AU780634C (https=) |
| CA (1) | CA2398571A1 (https=) |
| WO (1) | WO2001058494A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
| JP2006516027A (ja) * | 2002-12-02 | 2006-06-15 | ジェンベク、インコーポレイティッド | 眼関連障害の治療用材料および治療方法 |
| US20040166091A1 (en) | 2003-02-24 | 2004-08-26 | Genvec, Inc. | Materials and methods for treating disorders of the ear |
| WO2006054278A2 (en) | 2004-11-16 | 2006-05-26 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Variants of pigment epithelium derived factor and uses thereof |
| WO2006123248A2 (en) * | 2005-04-18 | 2006-11-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Improved methods and devices for delivering a therapeutic product to the ocular sphere of a subject |
| JP2007291009A (ja) * | 2006-04-25 | 2007-11-08 | Seitai Shigen Laboratory Inc | 血管内膜肥厚抑制剤 |
| WO2009126894A2 (en) * | 2008-04-11 | 2009-10-15 | Massachusetts Eye And Ear Infirmary | Methods and compositions for the diagnosis and treatment of angiogenic disorders |
| CN104619727B (zh) * | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| ES2667209T3 (es) * | 2013-03-14 | 2018-05-10 | Asklepios Biopharmaceutical, Inc. | Genes del receptor-1 de VEGF soluble modificado y vectores para terapia génica |
| TWI710635B (zh) | 2014-10-09 | 2020-11-21 | 美商珍維克公司 | 編碼人類無調同源物-1(hath1)之腺病毒載體 |
| US12305185B2 (en) | 2018-01-23 | 2025-05-20 | Mount Spec Investments Pty Ltd | Expression vector and method |
| US10632211B2 (en) | 2018-06-11 | 2020-04-28 | The Regents Of The University Of California | Demethylation to treat eye disease |
| CN112566622A (zh) * | 2018-06-19 | 2021-03-26 | 细胞疗法有限责任公司 | 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统 |
| WO2019246141A1 (en) | 2018-06-19 | 2019-12-26 | Cella Therapeutics, Llc | DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-α (TNF-α) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE |
| CN118767143A (zh) | 2019-12-12 | 2024-10-15 | 听治疗有限责任公司 | 用于预防和治疗听力损失的组合物和方法 |
| US20230094423A1 (en) * | 2019-12-18 | 2023-03-30 | Cella Therapeutics, Llc | Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-alpha (tnf-alpha) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995033480A1 (en) * | 1994-06-07 | 1995-12-14 | The Government Of The United States Of America, Re | Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene |
| US5840686A (en) * | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5461749A (en) * | 1994-05-31 | 1995-10-31 | Minnesota Mining And Manufacturing Company | Floor mop and cleaning system |
| US5904144A (en) * | 1996-03-22 | 1999-05-18 | Cytotherapeutics, Inc. | Method for treating ophthalmic diseases |
| CA2298018C (en) * | 1997-07-23 | 2008-12-16 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
| JP2001517455A (ja) * | 1997-09-23 | 2001-10-09 | ジェンベク、インコーポレイティッド | 真核生物ウイルスベクター構築用プラスミド |
| WO1999026480A1 (en) * | 1997-11-20 | 1999-06-03 | Genetix Pharmaceuticals, Inc. | Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases |
| AU3755900A (en) * | 1999-03-15 | 2000-10-04 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
-
2001
- 2001-02-09 JP JP2001557602A patent/JP2003522160A/ja active Pending
- 2001-02-09 EP EP01909022A patent/EP1253948A2/en not_active Withdrawn
- 2001-02-09 AU AU36818/01A patent/AU780634C/en not_active Ceased
- 2001-02-09 CA CA002398571A patent/CA2398571A1/en not_active Abandoned
- 2001-02-09 WO PCT/US2001/004203 patent/WO2001058494A2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840686A (en) * | 1992-09-24 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use |
| WO1995033480A1 (en) * | 1994-06-07 | 1995-12-14 | The Government Of The United States Of America, Re | Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003522160A (ja) | 2003-07-22 |
| CA2398571A1 (en) | 2001-08-16 |
| AU780634B2 (en) | 2005-04-07 |
| WO2001058494A2 (en) | 2001-08-16 |
| WO2001058494A3 (en) | 2002-04-04 |
| EP1253948A2 (en) | 2002-11-06 |
| AU3681801A (en) | 2001-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030045498A1 (en) | Materials and methods for treating ocular-related disorders | |
| US7989426B2 (en) | Selective induction of apoptosis to treat ocular disease by expression of PEDF | |
| US20090018100A1 (en) | Materials and methods for treating ocular-related disorders | |
| US20090041759A1 (en) | Materials and methods for treating ocular-related disorders | |
| AU780634C (en) | Gene Therapy for treating ocular-related disorders | |
| US8338384B2 (en) | Method for treating ocular neovascularization | |
| HK1203216A1 (en) | Materials and methods for treating disorders of the ear | |
| Mori et al. | Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies | |
| US20090149381A1 (en) | Methods of regulating angiogenesis through stabilization of PEDF | |
| Hamilton et al. | Alternate serotype adenovector provides long-term therapeutic gene expression in the eye | |
| US20050260180A1 (en) | Materials and methods for treating vascular leakage in the eye | |
| JP2000510449A (ja) | 増殖性硝子体網膜症に対する遺伝子治療 | |
| WO2005105155A1 (en) | Methods for delivering a gene product to the eye | |
| AU2005202935A1 (en) | Gene therapy for treating ocular-related disorders | |
| US20060188481A1 (en) | Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder | |
| Otsuji et al. | In vivo gene transfer into choroidal neovascularization by the HVJ liposome method | |
| JP4612417B2 (ja) | 眼の遺伝子治療 | |
| Anzai et al. | Laser Photocoagulation and, to a Lesser Extent, Photodynamic Therapy Target and Enhance Adenovirus Vector–Mediated Gene Transfer in the Rat Retina |